

# Clinical Oversight Review Board (CORB) Criteria for Prescribing Lurbinectedin (Zepzelca)

Non-Formulary **lurbinectedin (Zepzelca)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

**Initiation (new start) criteria:** Non-formulary **lurbinectedin (Zepzelca)** will be covered on the prescription drug benefit for \*\*\* months when the following criteria are met:

- Patient is at least 18 years of age
- Diagnosis of metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy
- Confirmed history of using cisplatin- or carboplatin-based regimen for the treatment of SCLC
- Either of the following clinical conditions:
  - For patients with relapse >6 months from platinum-based chemotherapy: a predicted or documented intolerance/contraindication to the original regimen
  - OR-**
  - For patients with relapse ≤6 months from platinum-based chemotherapy: A predicted or documented intolerance/contraindication to topotecan OR progression/refractory to topotecan